Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases.

Abstract

To evaluate the activity of posaconazole for treatment of zygomycosis, a disease for which therapeutic options are limited, we conducted a retrospective study including 91 patients with zygomycosis (proven zygomycosis, 69 patients; probable zygomycosis, 22 patients). Patients had infection that was refractory to prior antifungal treatment (n=81) or were intolerant of such treatment (n=10) and participated in the compassionate-use posaconazole (800 mg/day) program. The rate of success (i.e., either complete or partial response) at 12 weeks after treatment initiation was 60%, and 21% of patients had stable disease. The overall high success and survival rates reported here provide encouraging data regarding posaconazole as an alternative therapy for zygomycosis.

• Authors: Jo-Anne H van Burik, Roberta S Hare, Howard F Solomon, Michael L Corrado, Dimitrios P Kontoyiannis
• Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (Clin Infect Dis) Vol. 42 Issue 7 Pg. e61-5 (Apr 01 2006) ISSN: 1537-6591 [Electronic] United States
• PMID: 16511748 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antifungal Agents
• Triazoles
• posaconazole

Topics

• Adolescent
• Adult
• Aged
• Aged, 80 and over
• Antifungal Agents (therapeutic use)
• Child
• Female
• Humans
• Male
• Middle Aged
• Retrospective Studies
• Salvage Therapy
• Triazoles (therapeutic use)
• Zygomycosis (drug therapy)